Kanser Tedavilerinin Semptom ve Toksisite Yönetimi
Özet
Kanser tedavilerinde yaygın kullanılan kemoterapötik ajanlar, hızlı bölünen sağlıklı hücrelere de zarar vererek çeşitli sistemik toksisitelere ve ciddi semptomlara yol açmaktadır. Kemoterapi ilişkili nörotoksiteler özellikle taksanlar ve platinumlar gibi ilaçlarla tetiklenmekte; akut nöropati soğuğa duyarlılık ve kas krampları ile kendini gösterirken, klinik yönetimde duruma göre doz azaltımı veya duloksetin kullanımı önerilmektedir. Antrasiklinlerin en sık neden olduğu kardiyak toksisite durumunda ise kümülatif doza bağlı kardiyomiyopati gelişi gözlenmekte, risk yönetimi ve biyobelirteç takibi önem arz etmektedir. Gastrointestinal sistemde emetik şiddete göre antiemetik tedaviler uygulanırken; hayatı tehdit eden dehidratasyona ve sese yol açabilen diyare durumunda loperamid ve sıvı replasmanı devreye girmektedir. Kemik iliği baskılanması sonucu anemi, nötropeni ve trombositopeni gelişerek enfeksiyon ile kanama riskleri artmakta, yönetimde büyüme faktörleri ve replasmanlar kullanılmaktadır. Ek olarak, hastaların %65’ini etkileyen saç dökülmesine karşı skalp soğutma uygulanabilirken; bleomisin gibi ajanların tetiklediği pulmoner hasarlarda kortikosteroidler ve destekleyici oksijen tedavisi ampirik olarak tercih edilmektedir. Son olarak, karaciğer sinüzoidleri ile hepatositlerin hasar gördüğü hepatotoksitede ilaç dozaj ayarları yapılırken; glomerulus ve tübülleri etkileyen renal toksisiteyi önlemek adına sisplatin hastalarında intravenöz salin, mannitol ve magnezyum replasmanından faydalanılmaktadır.
Chemotherapeutic agents commonly used in cancer treatments also damage rapidly dividing healthy cells, leading to various systemic toxicities and severe symptoms. Chemotherapy-induced neurotoxicities are especially triggered by drugs such as taxanes and platinums; while acute neuropathy manifests as cold sensitivity and muscle cramps, dose reduction or the use of duloxetine is recommended in clinical management depending on the situation. In cardiac toxicity, most commonly caused by anthracyclines, cumulative dose-dependent cardiomyopathy is observed, and risk management along with biomarker monitoring is of great importance. While antiemetic treatments are applied in the gastrointestinal system according to emetic severity, loperamide and fluid replacement are utilized in cases of diarrhea, which can lead to life-threatening dehydration and sepsis. Bone marrow suppression results in anemia, neutropenia, and thrombocytopenia, increasing the risks of infection and bleeding, and growth factors and replacements are used in its management. Additionally, scalp cooling can be applied against hair loss affecting 65% of patients, whereas in pulmonary injuries triggered by agents like bleomycin, corticosteroids and supportive oxygen therapy are empirically preferred. Finally, while drug dosage adjustments are made in hepatotoxicity where liver sinusoids and hepatocytes are damaged, intravenous saline, mannitol, and magnesium replacement are utilized in cisplatin patients to prevent renal toxicity affecting the glomerulus and tubules.
Referanslar
Remesh A. Toxicities of anticancer drugs and its management. International journal of basic and clinical pharmacology. 2012;1:2-12.
Reeves BN, Dakhil SR, Sloan JA, et al. Further data supporting that paclitaxel-associated acute pain syndrome is associated with development of peripheral neuropathy: North Central Cancer Treatment Group trial N08C1. Cancer. 2012;118(20):5171-5178. doi:10.1002/cncr.27489.
Loprinzi CL, Reeves BN, Dakhil SR, et al. Natural history of paclitaxel-associated acute pain syndrome: prospective cohort study NCCTG N08C1. J Clin Oncol. 2011;29(11):1472-1478. doi:10.1200/JCO.2010.33.0308.
Pachman DR, Qin R, Seisler DK, et al. Clinical Course of Oxaliplatin-Induced Neuropathy: Results From the Randomized Phase III Trial N08CB (Alliance). J Clin Oncol. 2015;33(30):3416-3422. doi:10.1200/JCO.2014.58.8533.
Pachman DR, Qin R, Seisler D, et al. Comparison of oxaliplatin and paclitaxel-induced neuropathy (Alliance A151505). Support Care Cancer. 2016;24(12):5059-5068. doi:10.1007/s00520-016-3373-1.
Loprinzi CL, Maddocks-Christianson K, Wolf SL, et al. The Paclitaxel acute pain syndrome: sensitization of nociceptors as the putative mechanism. Cancer J. 2007;13(6):399-403. doi:10.1097/PPO.0b013e31815a999b.
Bandos H, Melnikow J, Rivera DR, et al. Long-term Peripheral Neuropathy in Breast Cancer Patients Treated With Adjuvant Chemotherapy: NRG Oncology/NSABP B-30. J Natl Cancer Inst. 2018;110(2):djx162. doi:10.1093/jnci/djx162.
Hershman DL, Unger JM, Crew KD, et al. Two-Year Trends of Taxane-Induced Neuropathy in Women Enrolled in a Randomized Trial of Acetyl-L-Carnitine (SWOG S0715). J Natl Cancer Inst. 2018;110(6):669-676. doi:10.1093/jnci/djx259.
Loprinzi CL, Lacchetti C, Bleeker J, et al. Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: ASCO Guideline Update. J Clin Oncol. 2020;38(28):3325-3348. doi:10.1200/JCO.20.01399.
Keizer HG, Pinedo HM, Schuurhuis GJ, Joenje H. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacol Ther. 1990;47(2):219-231. doi:10.1016/0163-7258(90)90088-j.
Hardy D, Liu CC, Cormier JN, Xia R, Du XL. Cardiac toxicity in association with chemotherapy and radiation therapy in a large cohort of older patients with non-small-cell lung cancer. Ann Oncol. 2010;21(9):1825-1833. doi:10.1093/annonc/mdq042.
Armenian SH, Lacchetti C, Barac A, et al. Prevention and Monitoring of Cardiac Dysfunction in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline. J Clin Oncol. 2017;35(8):893-911. doi:10.1200/JCO.2016.70.5400.
Dranitsaris G, Molassiotis A, Clemons M, et al. The development of a prediction tool to identify cancer patients at high risk for chemotherapy-induced nausea and vomiting. Ann Oncol. 2017;28(6):1260-1267. doi:10.1093/annonc/mdx100.
Hesketh PJ, Kris MG, Basch E, et al. Antiemetics: American Society of Clinical Oncology Clinical Practice Guideline Update. J Clin Oncol. 2017;35(28):3240-3261. doi:10.1200/JCO.2017.74.4789.
Conti JA, Kemeny NE, Saltz LB, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol. 1996;14(3):709-715. doi:10.1200/JCO.1996.14.3.709
Leichman CG, Fleming TR, Muggia FM, et al. Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a Southwest Oncology Group study. J Clin Oncol. 1995;13(6):1303-1311. doi:10.1200/JCO.1995.13.6.1303.
Rothenberg ML, Eckardt JR, Kuhn JG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol. 1996;14(4):1128-1135. doi:10.1200/JCO.1996.14.4.1128.
Wadler S, Haynes H, Wiernik PH. Phase I trial of the somatostatin analog octreotide acetate in the treatment of fluoropyrimidine-induced diarrhea. J Clin Oncol. 1995;13(1):222-226. doi:10.1200/JCO.1995.13.1.222.
Rutledge DN, Engelking C. Cancer-related diarrhea: selected findings of a national survey of oncology nurse experiences. Oncol Nurs Forum. 1998;25(5):861-873.
Arbuckle RB, Huber SL, Zacker C. The consequences of diarrhea occurring during chemotherapy for colorectal cancer: a retrospective study. Oncologist. 2000;5(3):250-259. doi:10.1634/theoncologist.5-3-250.
Benson AB 3rd, Ajani JA, Catalano RB, et al. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004;22(14):2918-2926. doi:10.1200/JCO.2004.04.132
Barreto JN, McCullough KB, Ice LL, Smith JA. Antineoplastic agents and the associated myelosuppressive effects: a review. J Pharm Pract. 2014;27(5):440-446. doi:10.1177/0897190014546108.
Delforge M, Ludwig H. How I manage the toxicities of myeloma drugs. Blood. 2017;129(17):2359-2367. doi:10.1182/blood-2017-01-725705.
Smith RE. Trends in recommendations for myelosuppressive chemotherapy for the treatment of solid tumors. J Natl Compr Canc Netw. 2006;4(7):649-658. doi:10.6004/jnccn.2006.0056.
Kuter DJ. Managing thrombocytopenia associated with cancer chemotherapy. Oncology (Williston Park). 2015;29(4):282-294.
Taylor SJ, Duyvestyn JM, Dagger SA, et al. Preventing chemotherapy-induced myelosuppression by repurposing the FLT3 inhibitor quizartinib. Sci Transl Med. 2017;9(402):eaam8060. doi:10.1126/scitranslmed.aam8060.
Bryer E, Henry D. Chemotherapy-induced anemia: etiology, pathophysiology, and implications for contemporary practice. International Journal of Clinical Transfusion Medicine. 2018;6:21-31. https://doi.org/10.2147/IJCTM.S187569
Aapro M, Beguin Y, Bokemeyer C, et al. Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines [published correction appears in Ann Oncol. 2018 Oct 1;29(Suppl 4):iv271]. Ann Oncol. 2018;29(Suppl 4):iv96-iv110. doi:10.1093/annonc/mdx758.
Klastersky J, de Naurois J, Rolston K, et al. Management of febrile neutropaenia: ESMO Clinical Practice Guidelines. Ann Oncol. 2016;27(suppl 5):v111-v118. doi:10.1093/annonc/mdw325.
Crawford J, Denduluri N, Patt D, et al. Relative dose intensity of first-line chemotherapy and overall survival in patients with advanced non-small-cell lung cancer. Support Care Cancer. 2020;28(2):925-932. doi:10.1007/s00520-019-04875-1.
Balagula Y, Rosen ST, Lacouture ME. The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol. 2011;65(3):624-635. doi:10.1016/j.jaad.2010.06.051.
Trüeb RM. Chemotherapy-induced hair loss. Skin Therapy Lett. 2010;15(7):5-7.
Rossi A, Caro G, Fortuna MC, Pigliacelli F, D'Arino A, Carlesimo M. Prevention and Treatment of Chemotherapy-Induced Alopecia. Dermatol Pract Concept. 2020;10(3):e2020074. Published 2020 Jun 29. doi:10.5826/dpc.1003a74
Shannon VR. Cancer Treatment-Related Lung Injury. Oncologic Critical Care. 2019;531-556. Published 2019 Jul 9. doi:10.1007/978-3-319-74588-6_52.
Vahid B, Marik PE. Pulmonary complications of novel antineoplastic agents for solid tumors. Chest. 2008;133(2):528-538. doi:10.1378/chest.07-0851.
Skeoch S, Weatherley N, Swift AJ, et al. Drug-Induced Interstitial Lung Disease: A Systematic Review. J Clin Med. 2018;7(10):356. Published 2018 Oct 15. doi:10.3390/jcm7100356.
Jaeschke H, Gores GJ, Cederbaum AI, Hinson JA, Pessayre D, Lemasters JJ. Mechanisms of hepatotoxicity. Toxicol Sci. 2002;65(2):166-176. doi:10.1093/toxsci/65.2.166.
Fontana RJ. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology. 2014;146(4):914-928. doi:10.1053/j.gastro.2013.12.032.
Hoofnagle JH, Björnsson ES. Drug-Induced Liver Injury - Types and Phenotypes. N Engl J Med. 2019;381(3):264-273. doi:10.1056/NEJMra1816149.
Mudd TW, Guddati AK. Management of hepatotoxicity of chemotherapy and targeted agents. Am J Cancer Res. 2021;11(7):3461-3474. Published 2021 Jul 15.
Santos MLC, de Brito BB, da Silva FAF, Botelho ACDS, de Melo FF. Nephrotoxicity in cancer treatment: An overview. World J Clin Oncol. 2020;11(4):190-204. doi:10.5306/wjco.v11.i4.190.
Naughton CA. Drug-induced nephrotoxicity. Am Fam Physician. 2008;78(6):743-750.
Malyszko J, Kozlowska K, Kozlowski L, Malyszko J. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant. 2017;32(6):924-936. doi:10.1093/ndt/gfw338.
Chiruvella V, Annamaraju P, Guddati AK. Management of nephrotoxicity of chemotherapy and targeted agents: 2020. Am J Cancer Res. 2020;10(12):4151-4164. Published 2020 Dec 1.
